Akebia Therapeutics reports strong Q2 2025 earnings, driven by Vafseo’s 55% sales growth. Explore plans for expanded patient access & trial updates.

Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis ...

Company Announcement, European Regulatory News, GlobeNewswire, Pharmaceuticals | Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange L ...

Variety’s 2025 class of New Leaders is an antidote to that type of thinking, proving that a time of contraction and ...

The community of Cardigan celebrates the successful purchase and transformation of the Tabernacl Chapel into a vibrant ...

Moves in Charlotte must be planned in conjunction with the weather. The weather in the city has moods, and if you are moving in a rush, the last thing you need is a humid meltdown or a winter surprise ...

Saudi Arabia’s leading purpose-driven healthcare and wellbeing Company, today reported its financial results for the second ...

Procter & Gamble (PG) reported fourth quarter results, warning that it will take a $1 billion hit from tariffs in full-year ...

Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program Cont ...

Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., ...

At any given party in America right now, someone is meticulously destroying a beer label. While their mouth says "totally fine, thanks for asking," their fingers are conducting a careful archaeology ...

Jean-Baptiste Massignon, Managing Director of the EcoBeautyScore Association, examines how a new sustainability score is ...